The Latest
-
Alamy
Trump administration5 FDA decisions to watch in the third quarter of 2026
A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.
-
Permission granted by ICON plc
Sponsored by ICONFrom confidence to capital: Positioning biotech for the next growth cycle
How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.
-
Courtesy of Sanofi
Sanofi halts development of troubled immune drug in eczema
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
-
Getty Images
IPO windowScribe secures $129M in a rare gene editing IPO
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.
-
Scott Olson via Getty Images
Obesity drugsLilly, with new data, to seek FDA approval of obesity drug retatrutide
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Argenx is paying $2.2 billion to acquire Forte Biosciences, the developer of a CD122-targeting antibody drug that’s shown early promise against multiple immunological conditions.
Updated 11 hours ago -
Permission granted by Vertex Pharmaceuticals
Vertex was sole bidder in high-premium Crinetics acquisition
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Scribe’s IPO haul is the smallest among the 14 biotechs to go public this year. But the company is one of only two to price an offering without a drug that’s already in Phase 2 testing or later, data show.
Updated July 24, 2026 -
Getty Images
News roundupNovo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
-
Courtesy of GSK
GSK lung cancer drug gets speedy approval following $10.6B deal
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
-
Getty Images
Obesity drugsNovo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”
-
SpiffyJ via Getty Images
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
-
Alex Wong via Getty Images
Trump administrationTrump threatens tariffs on imported generic drugs
While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove more disruptive.
-
Permission granted by Dimension
Emerging biotechDimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.
-
Getty Images
Emerging biotechCrystalys nets $130M more to push gout drug through late-stage tests
The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.
-
Getty Images
News roundup
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
-
Getty Images
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
-
Getty Images
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
-
Getty Images
IPO windowPain drugmaker Latigo outlines plans to go public
The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
-
Getty Images
News roundup
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
-
Getty Images
Obesity drugsCompounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
-
Getty Images
Tempus to acquire cancer test maker Personalis for $1.5B
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
-
Getty Images
GSK shelves cough drug acquired in $2B deal
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
-
Getty Images
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
-
Courtesy of Merck & Co.
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.
Updated July 16, 2026 -
Getty Images
Emerging biotechBiotech startup funding gap widens despite rebound in VC investment
Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.
